Table 4.

Multivariate analysis of distant metastasis for propensity score-matched patients with breast cancer receiving total mastectomy under PB-RA with propofol or INHA-GA without propofol.

		DM
		aHR*	(95% CI)	p-value
Anesthesia	INHA-GA	ref		0.1369
	Propofol	0.74	(0.49–1.10)
Age (years)	20–49	ref		0.7548
	50+	0.94	(0.62–1.41)
Diagnosis year	2009–2013	ref		0.2296
	2014–2018	0.77	(0.50–1.18)
Menopausal status	Premenopausal	ref		0.4711
	Postmenopausal	0.79	(0.68–1.51)
CCI scores	0	ref		0.8673
	1	0.88	(0.54–1.43)
	2+	0.90	(0.47–1.72)
Differentiation	I	ref		0.7573
	II	1.26	(0.62–2.54)
	III	1.33	(0.63–2.82)
AJCC clinical stage	I	ref		0.0089
	II	1.15	(1.06–2.46)
	III	1.35	(1.12–2.92)
pT	pT1	ref		0.0015
	pT2	1.12	(1.02–2.21)
	pT3–4	2.01	(1.12–3.59)
pN	pN0	ref		0.0073
	pN1	1.24	(1.11–2.29)
	pN2–3	2.11	(1.22–3.64)
Nodal surgery	ALND	ref		0.2283
	SLNB	1.09	(0.88–3.25)
ASA	I	ref		0.9537
	II	1.07	(0.59–1.58)
	III–IV	1.12	(0.62–1.80)
Adjuvant chemotherapy	Yes	0.70	(0.46–0.96)	0.0157
Adjuvant RT	Yes	0.81	(0.52–1.26)	0.3475
HR	Positive	0.96	(0.73–1.55)	0.7624
HER2	Positive	2.06	(1.07–3.52)	<0.0001
Hospital level	Academic centers	ref		0.4898
	Nonacademic	0.85	(0.53–1.36)

PB-RA, paravertebral block-regional anesthesia; GA, general anesthesia; INHA, inhalational; aHR, adjusted hazard ratios; CIs, confidence intervals; AJCC, American Joint Committee on Cancer; HR, Hormone Receptor; HER2, Human Epidermal Growth Factor Receptor-2; RT, radiotherapy; ASA, American Society of Anesthesiology; CCI, Charlson comorbidity index; T, tumor; N, nodal; pT, pathological tumor stage; pN, pathological nodal stage; ALND, axillary lymph node dissection; SNLB, sentinel lymph node biopsy; ref, reference group.

*All covariates mentioned in Table 2 were adjusted.